𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis

✍ Scribed by Mark A. Chidel; John H. Suh; John F. Greskovich; Patrick A. Kupelian; Gene H. Barnett


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
143 KB
Volume
7
Category
Article
ISSN
1065-7541

No coin nor oath required. For personal study only.

✦ Synopsis


The purpose of this study was to evaluate the outcome of treatment for patients with newly diagnosed nonsmall-cell lung cancer (NSCLC) with an isolated, single, synchronous brain metastasis. A retrospective review was performed evaluating any patient diagnosed between 1982 and 1996 at the Cleveland Clinic Foundation with NSCLC metastatic only to the brain. Patients with multiple brain metastases or with systemic metastases to any other organ were excluded. Survival was measured from the date of the first treatment for malignancy. All hospital records were thoroughly reviewed in a retrospective manner. Thirty-three patients were identified who met the study criteria. Twelve patients had primary disease limited to the lung and hilar nodes, and 21 had more advanced primary disease with involvement of the mediastinum. Treatment of the chest was considered aggressive in 13 patients and palliative in 15. The primary tumor was observed in 5 patients. The management of the brain metastasis was as follows: 21 patients underwent surgical resection and postoperative whole brain radiotherapy (WBRT), 5 underwent stereotactic radiosurgery (SRS) and WBRT, 3 had resection alone, 2 had SRS alone, and 2 underwent WBRT alone. The median overall and disease-free survival for all patients was 6.9 months and 3.3 months, respectively. Overall survival was markedly improved with the addition of WBRT (P = 0.002) and with the aggressive management of the primary tumor (P = 0.005). A total of 9 patients experienced CNS failure, including both patients receiving WBRT alone. CNS failures were divided as follows: 3 local, 5 distant, and 1 local and distant. Two of the 4 patients with a local failure were salvaged, and ultimate local control of the original brain metastasis was achieved in 93.6% of cases. Survival remains poor for patients with Stage IV NSCLC even when metastatic disease is limited to a single site within the brain; however, aggressive therapy of both the lung primary and the brain metastasis may provide a survival advantage. Excellent local control of single brain metastases was achieved with a combination of WBRT with either surgical resection or SRS.


πŸ“œ SIMILAR VOLUMES


Stereotactic radiosurgery for patients w
✍ Young Soo Kim; Douglas Kondziolka; John C. Flickinger; L. Dade Lunsford πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 213 KB πŸ‘ 2 views

## Background: A retrospective study of patients undergoing stereotactic radiosurgery for one to four brain metastases from nonsmall lung cell carcinoma (nsclc) was performed to document outcomes and risks. ## Methods: Seventy-seven patients underwent radiosurgery during a 7-year interval; 71 als

Comparison of a genetic algorithm neural
✍ Miles F. Jefferson; Neil Pendleton; Sam B. Lucas; Michael A. Horan πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 1 views

of surgery in 620 patients with nonsmall cell lung carcinoma (NSCLC) by a genetic algorithm neural network (GANN) using Bayes' theorem compared with logistic 1 Department of Geriatric Medicine, Clinical Sciregression, and the predictive value of tumor volume measures in addition to ences Building, H

Front-line chemotherapy with cisplatin a
✍ Vittorio Franciosi; Giorgio Cocconi; Maria Michiara; Francesco Di Costanzo; Vini πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 74 KB πŸ‘ 2 views

## BACKGROUND. The conventional treatment of brain metastases not amenable to surgery is most often radiotherapy. Until now, pharmacologic issues related to the blood brain barrier (BBB) prevented a wide evaluation of chemotherapy. The authors previously reported that the combination of cisplatin